(CLYM) Climb Bio - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 631m USD | Total Return: 816.7% in 12m
Avg Turnover: 7.64M
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader, Confidence
Climb Bio, Inc. (formerly Eliem Therapeutics) is a clinical-stage biotechnology firm specialized in monoclonal antibody therapies for immune-mediated and B-cell driven diseases. The company’s primary focus is the development of budoprutug, an anti-CD19 antibody currently undergoing Phase 2 trials for primary membranous nephropathy and immune thrombocytopenia, alongside Phase 1b trials for systemic lupus erythematosus.
The company operates within the high-risk, high-reward biotechnology sector, where value is primarily derived from clinical trial milestones and intellectual property rather than immediate revenue. Its pipeline also includes CLYM116, a preclinical candidate targeting A Proliferation-inducing Ligand (APRIL) for the treatment of immunoglobulin A nephropathy. To assess the long-term viability of these clinical assets, investors can review detailed pipeline projections on ValueRay.
Headquartered in Wellesley Hills, Massachusetts, Climb Bio utilizes a business model centered on the research and development of targeted biologics. Monoclonal antibodies like budoprutug are designed to bind to specific proteins on cell surfaces, a precision approach common in modern immunology intended to reduce the systemic side effects associated with broader immunosuppressants.
- Budoprutug clinical trial data readouts for multiple B-cell mediated indications
- FDA regulatory milestones for lead anti-CD19 monoclonal antibody candidate
- Cash runway and funding requirements for advancing preclinical pipeline assets
- Competitive landscape for systemic lupus erythematosus and primary membranous nephropathy treatments
- Strategic shift and operational execution following Eliem Therapeutics rebranding to Climb Bio
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -20.57 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.35 > 3% & CFO -53.3m > Net Income -52.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.2m) vs 12m ago 1.10% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.72 (Total Current Assets 113.4m - Total Current Liabilities 4.07m) / Total Assets 152.4m |
| B: -1.99 (Retained Earnings -303.4m / Total Assets 152.4m) |
| C: -0.32 (EBIT TTM -56.1m / Avg Total Assets 176.6m) |
| D: -70.75 (Book Value of Equity -303.3m / Total Liabilities 4.29m) |
| Altman-Z'' = -78.20 = D |
As of May 24, 2026, the stock is trading at USD 10.91 with a total of 597,688 shares traded.
Over the past week, the price has changed by +1.85%,
over one month by +18.28%,
over three months by +88.68% and
over the past year by +816.67%.
Climb Bio has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CLYM.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.8 | 81.2% |
Revenue TTM = 0.0 USD
EBIT TTM = -56.1m USD
EBITDA TTM = -55.9m USD
Long Term Debt = 216k USD (estimated: total debt 479k - short term 263k)
Short Term Debt = 263k USD (from shortTermDebt, last quarter)
Debt = 479k USD (from shortLongTermDebtTotal, last quarter) (leases 479k already included)
Net Debt = -109.1m USD (calculated: Debt 479k - CCE 109.6m)
Enterprise Value = 521.6m USD (630.7m + Debt 479k - CCE 109.6m)
Interest Coverage Ratio = unknown (Ebit TTM -56.1m / Interest Expense TTM 0.0)
EV/FCF = -9.75x (Enterprise Value 521.6m / FCF TTM -53.5m)
FCF Yield = -10.25% (FCF TTM -53.5m / Enterprise Value 521.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 135k) / Revenue TTM)
Tobins Q-Ratio = 3.42 (Enterprise Value 521.6m / Total Assets 152.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 479k)
Taxrate = 21.0% (US default 21%)
NOPAT = -44.3m (EBIT -56.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.86 (Total Current Assets 113.4m / Total Current Liabilities 4.07m)
Debt / Equity = 0.00 (Debt 479k / totalStockholderEquity, last quarter 148.1m)
Debt / EBITDA = 1.95 (negative EBITDA) (Net Debt -109.1m / EBITDA -55.9m)
Debt / FCF = 2.04 (negative FCF - burning cash) (Net Debt -109.1m / FCF TTM -53.5m)
Total Stockholder Equity = 167.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.90% (Net Income -52.8m / Total Assets 152.4m)
RoE = -11.20% (Net Income TTM -52.8m / Total Stockholder Equity 471.3m)
RoCE = -11.89% (EBIT -56.1m / Capital Employed (Equity 471.3m + L.T.Debt 216k))
RoIC = -113.6% (out of range, set to none) (NOPAT -44.3m / Invested Capital 39.0m)
WACC = 7.50% (E(630.7m)/V(631.2m) * Re(7.51%) + D(479k)/V(631.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 50.19%
[DCF] Fair Price = unknown (Cash Flow -53.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.23 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.22 | Chg30d=+20.91% | Revisions=+56% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.21 | Chg30d=+24.54% | Revisions=+56% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.87 | Chg30d=+24.49% | Revisions=+56% | GrowthEPS=+1.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.12 | Chg30d=+23.14% | Revisions=+20% | GrowthEPS=-29.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +56%